![](/images/graphics-bg.png)
Astragaloside IV Exerts a Myocardial Protective Effect against Cardiac Hypertrophy in Rats, Partially via Activating the Nrf2HO-1 Signaling Pathway
Joint Authors
Shen, Cheng
Nie, Pei
Meng, Fanjing
Zhang, Jinguo
Wei, Xiqing
Source
Oxidative Medicine and Cellular Longevity
Issue
Vol. 2019, Issue 2019 (31 Dec. 2019), pp.1-16, 16 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2019-06-11
Country of Publication
Egypt
No. of Pages
16
Main Subjects
Abstract EN
Previous evidence suggested that astragaloside IV (ASIV) had a cardioprotective effect, but the potential mechanisms were undetermined.
This study is aimed at validating the prevention of cardiac hypertrophy in chronic heart failure (CHF) rats and hypertrophy in H9c2 cardiomyocytes by ASIV and at exploring the potential mechanism involved.
CHF rat models of abdominal aortic constriction (AAC) were used with the aim of determining the protective effect of ASIV in cardiac hypertrophy in the rats.
We proved that ASIV could attenuate cardiac hypertrophy by improving left ventricular function and structure and showed that the expression of nuclear factor-erythroid 2-related factor 2 (Nrf2) and its downstream gene heme oxygenase-1 (HO-1) increased in the high-dose ASIV intervention group.
To further investigate the specific mechanism of ASIV, we hypothesized that ASIV might prevent cardiac hypertrophy via activating the Nrf2/HO-1 signaling pathway.
We established a cardiomyocyte hypertrophy model induced by angiotensin II (Ang II), which was then transfected with Nrf2 shRNA, to knock down the expression of the Nrf2 gene.
We found that the protective effect of ASIV against Ang II-induced cardiomyocyte hypertrophy was abolished in the Nrf2 shRNA transfection group, ultimately aggravating cardiomyocyte hypertrophy induced by Ang II, and it is possible that oxidative stress may be involved in this process.
Our results demonstrated that ASIV improved cardiac function and inhibited cardiac hypertrophy by upregulating Nrf2, and this effect was partially achieved by stimulating the Nrf2/HO-1 signaling pathway, suggesting that ASIV could have therapeutic potential for the treatment of cardiac hypertrophy and CHF.
American Psychological Association (APA)
Nie, Pei& Meng, Fanjing& Zhang, Jinguo& Wei, Xiqing& Shen, Cheng. 2019. Astragaloside IV Exerts a Myocardial Protective Effect against Cardiac Hypertrophy in Rats, Partially via Activating the Nrf2HO-1 Signaling Pathway. Oxidative Medicine and Cellular Longevity،Vol. 2019, no. 2019, pp.1-16.
https://search.emarefa.net/detail/BIM-1203759
Modern Language Association (MLA)
Nie, Pei…[et al.]. Astragaloside IV Exerts a Myocardial Protective Effect against Cardiac Hypertrophy in Rats, Partially via Activating the Nrf2HO-1 Signaling Pathway. Oxidative Medicine and Cellular Longevity No. 2019 (2019), pp.1-16.
https://search.emarefa.net/detail/BIM-1203759
American Medical Association (AMA)
Nie, Pei& Meng, Fanjing& Zhang, Jinguo& Wei, Xiqing& Shen, Cheng. Astragaloside IV Exerts a Myocardial Protective Effect against Cardiac Hypertrophy in Rats, Partially via Activating the Nrf2HO-1 Signaling Pathway. Oxidative Medicine and Cellular Longevity. 2019. Vol. 2019, no. 2019, pp.1-16.
https://search.emarefa.net/detail/BIM-1203759
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1203759